EBS vs RDY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and RDY is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EBS’s FA Score shows that 1 FA rating(s) are green whileRDY’s FA Score has 0 green FA rating(s).
- EBS’s FA Score: 1 green, 4 red.
- RDY’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EBS’s TA Score shows that 6 TA indicator(s) are bullish while RDY’s TA Score has 6 bullish TA indicator(s).
- EBS’s TA Score: 6 bullish, 3 bearish.
- RDY’s TA Score: 6 bullish, 3 bearish.
Price Growth
EBS (@Pharmaceuticals: Other) experienced а +9.92% price change this week, while RDY (@Pharmaceuticals: Other) price change was -4.29% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.06%. For the same industry, the average monthly price growth was +12.42%, and the average quarterly price growth was +15.65%.
Reported Earning Dates
EBS is expected to report earnings on Aug 12, 2025.
RDY is expected to report earnings on Jul 24, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-0.06% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| EBS | RDY | EBS / RDY | |
| Capitalization | 120M | 12.5B | 1% |
| EBITDA | -518.2M | 84.9B | -1% |
| Gain YTD | -40.900 | -15.136 | 270% |
| P/E Ratio | 17.73 | 19.68 | 90% |
| Revenue | 1.02B | 271B | 0% |
| Total Cash | 112M | 72.4B | 0% |
| Total Debt | 860M | 19.9B | 4% |
EBS | RDY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 37 | |
SMR RATING 1..100 | 92 | 45 | |
PRICE GROWTH RATING 1..100 | 45 | 57 | |
P/E GROWTH RATING 1..100 | 10 | 62 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (57) in the Biotechnology industry is in the same range as RDY (79) in the Pharmaceuticals Generic industry. This means that EBS’s stock grew similarly to RDY’s over the last 12 months.
RDY's Profit vs Risk Rating (37) in the Pharmaceuticals Generic industry is somewhat better than the same rating for EBS (100) in the Biotechnology industry. This means that RDY’s stock grew somewhat faster than EBS’s over the last 12 months.
RDY's SMR Rating (45) in the Pharmaceuticals Generic industry is somewhat better than the same rating for EBS (92) in the Biotechnology industry. This means that RDY’s stock grew somewhat faster than EBS’s over the last 12 months.
EBS's Price Growth Rating (45) in the Biotechnology industry is in the same range as RDY (57) in the Pharmaceuticals Generic industry. This means that EBS’s stock grew similarly to RDY’s over the last 12 months.
EBS's P/E Growth Rating (10) in the Biotechnology industry is somewhat better than the same rating for RDY (62) in the Pharmaceuticals Generic industry. This means that EBS’s stock grew somewhat faster than RDY’s over the last 12 months.
| EBS | RDY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 3 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 52% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 53% |
| MACD ODDS (%) | N/A | 2 days ago 57% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 50% |
| TrendMonth ODDS (%) | 2 days ago 75% | 2 days ago 45% |
| Advances ODDS (%) | 16 days ago 76% | 24 days ago 50% |
| Declines ODDS (%) | 4 days ago 90% | 5 days ago 50% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 88% | N/A |
EBS and
Correlation & Price change
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with AMRX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then AMRX could also see price increases.
| Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
|---|---|---|---|---|
| EBS | 100% | -11.16% | ||
| AMRX - EBS | 33% Loosely correlated | -0.67% | ||
| HROW - EBS | 31% Poorly correlated | +3.43% | ||
| VTRS - EBS | 29% Poorly correlated | -3.52% | ||
| ZOMDF - EBS | 29% Poorly correlated | -4.46% | ||
| PAHC - EBS | 27% Poorly correlated | +0.99% | ||
More | ||||
RDY and
Correlation & Price change
A.I.dvisor tells us that RDY and KMDA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and KMDA's prices will move in lockstep.
| Ticker / NAME | Correlation To RDY | 1D Price Change % | ||
|---|---|---|---|---|
| RDY | 100% | +1.67% | ||
| KMDA - RDY | 32% Poorly correlated | -1.57% | ||
| COLL - RDY | 26% Poorly correlated | +5.94% | ||
| TAK - RDY | 25% Poorly correlated | +0.63% | ||
| SNDL - RDY | 24% Poorly correlated | -1.53% | ||
| ZTS - RDY | 24% Poorly correlated | -1.50% | ||
More | ||||